Mental disorders and cognitive impairment in patients with antiphospholipid syndrome

Cover Page

Cite item

Full Text

Abstract

Mental disorders (mainly anxiety and depressive disorders) and cognitive impairment are often found in patients with antiphospholipid syndrome (APS), but their prevalence, structure, and mechanisms of occurrence are not well researched. The review provides literature data on the frequency, spectrum and possible causes of mental disorders and cognitive impairment in patients with APS, the pathogenetic mechanisms of these disorders (in particular, the important role of antiphospholipid antibodies, stress factors, chronic inflammation), the relationship between APS, mental disorders and as well as cognitive impairment is examined. Special attention is paid to the influence of mental disorders and cognitive impairment on patients’ adherence to treatment, their quality of life, as well as the particularities of psychopharmacotherapy of mental disorders in patients with APS. The aim of the review is to actualize the interdisciplinary problem of mental disorders and cognitive impairment in patients with APS and the need to introduce a partnership model of care.

About the authors

A. B. Borisova

Moscow Research Institute of Psychiatry – branch of Serbskiy National Medical Research Center for Psychiatry and Addiction

Author for correspondence.
Email: desolatorius@yandex.ru
ORCID iD: 0000-0001-6802-0268

мл. науч. сотр. отд-ния психических расстройств при соматических заболеваниях

Russian Federation, Moscow

T. A. Lisitsyna

Nasonova Research Institute of Rheumatology

Email: desolatorius@yandex.ru
ORCID iD: 0000-0001-9437-406X

д.м.н., вед. науч. сотр. лаб. сосудистой ревматологии

Russian Federation, Moscow

D. Yu. Veltishchev

Moscow Research Institute of Psychiatry – branch of Serbskiy National Medical Research Center for Psychiatry and Addiction; Pirogov Russian National Research Medical University

Email: desolatorius@yandex.ru

д.м.н., проф. каф. психиатрии

 
Russian Federation, Moscow

T. M. Reshetnyak

Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuous Professional Education

Email: desolatorius@yandex.ru
ResearcherId: T-9886-2018

д.м.н., проф. каф. ревматологии; рук. лаб. сосудистой ревматологии

 
Russian Federation, Moscow

O. F. Seravina

Moscow Research Institute of Psychiatry – branch of Serbskiy National Medical Research Center for Psychiatry and Addiction

Email: desolatorius@yandex.ru

науч. сотр. отд-ния психических расстройств при соматических заболеваниях

Russian Federation, Moscow

O. B. Kovalevskaya

Moscow Research Institute of Psychiatry – branch of Serbskiy National Medical Research Center for Psychiatry and Addiction

Email: desolatorius@yandex.ru

науч. сотр. отд-ния психических расстройств при соматических заболеваниях

Russian Federation, Moscow

V. N. Krasnov

Moscow Research Institute of Psychiatry – branch of Serbskiy National Medical Research Center for Psychiatry and Addiction; Pirogov Russian National Research Medical University

Email: desolatorius@yandex.ru
ResearcherId: A-5117-2013

рук. отд.; зав. каф. психиатрии

Russian Federation, Moscow

E. L. Nasonov

Nasonova Research Institute of Rheumatology

Email: desolatorius@yandex.ru

науч. рук.

Russian Federation, Moscow

References

  1. Российские клинические рекомендации. Ревматология. Под ред. Е.Л. Насонова. М.: ГЭОТАР-Медиа, 2017: Решетняк Т.М. Антифосфолипидный синдром; с. 137-41 [Russian clinical recommendations. Rheumatology. edited by E.L. Nasonov. Moscow: GEOTAR-Media, 2017: Reshetnyak TM. Antiphospholipid syndrome; p. 137-41 (In Russ.)].
  2. Cervera R. Antiphospholipid syndrome. Thromb Res. 2017;151(1):43-7. doi: 10.1016/j.mpmed.2017.11.006
  3. Rege S, Mackworth-Young C. Antiphospholipid antibodies as biomarkers in psychiatry: review of psychiatric manifestations in antiphospholipid syndrome. Translate Develop Psychiatry. 2015;3(1):25452. doi: 10.3402/tdp.v3.25452
  4. Ricarte IF, Dutra LA, Abrantes FF, et al. Neurologic manifestations of antiphospholipid syndrome. Lupus. 2018. doi: 10.1177/0961203318776110
  5. Graf J. Central Nervous System Manifestations of Antiphospholipid Syndrome. Rheum Dis Clin North Am. 2017;43(4):547-60. doi: 10.1016/j.rdc.2017.06.004
  6. Regina P, Pnina R, Natur A, Levy Y. Anti-phospholipid syndrome associated with schizophrenia description of five patients and review of the literature. Immunol Res. 2017;65(2):438-46. doi: 10.1007/s12026-017-8895-1
  7. Avari JN, Young RC. A patient with bipolar disorder and antiphospholipid syndrome. J Geriatr Psychiatry Neurol. 2012;25(1):26-8. doi: 10.1177/0891988712436691
  8. Gris JC, Nobile B, Bouvier S. Neuropsychiatric presentations of antiphospholipid antibodies. Thromb Res. 2015;135(S1):S56-S59. doi: 10.1016/S0049-3848(15)50445-3
  9. Hallab A, Naveed S, Altibi A, et al. Association of psychosis with antiphospholipid antibody syndrome: A systematic review of clinical studies. Gen Hosp Psychiatry. 2018;50:137-47. doi: 10.1016/j.genhosppsych.2017.11.005
  10. Hoirisch-Clapauch S, Nardi AE. Psychiatric remission with warfarin: Should psychosis be addressed as plasminogen activator imbalance? Med Hypotheses. 2013;80(2):137-41. doi: 10.1016/j.mehy.2012.11.011
  11. Cardinal RN, Shah DN, Edwards CJ, et al. Psychosis and catatonia as a first presentation of antiphospholipid syndrome. Br J Psychiatry. 2009;195(3):268. doi: 10.1192/bjp.195.3.272
  12. Shabana M, Shalaby M, Alhumayed SAA. Paediatric case report: Primary antiphospholipid syndrome presented with non-thrombotic neurological picture psychosis; treat by antidepressants alone? Int J Rheum Dis. 2009;12(2):170-3. doi: 10.1111/j.1756-185X.2009.01401.x
  13. Raza H, Epstein SA, Pao M, Rosenstein DL. Mania: Psychiatric Manifestations of the Antiphospholipid Syndrome. Psychosomatics. 2008;49(5):438-41. doi: 10.1176/appi.psy.49.5.438
  14. Li CH, Chou MC, Liu CK, Lai CL. Antiphospholipid syndrome presenting as progressive neuropsychiatric disorders: Two case reports. Neuropsy Dis Treatment. 2013;9:739-42. doi: 10.2147/NDT.S44140
  15. Sadetski M, Tourinho Moretto ML, et al. Frequency of psychological alterations in primary antiphospholipid syndrome: preliminary study. Lupus. 2018;27(5):837-40. doi: 10.1177/0961203317751063
  16. Gris JC, Cyprien F, Bouvier S, et al. Antiphospholipid antibodies are associated with positive screening for common mental disorders in women with previous pregnancy loss. The NOHA-PSY observational study. World J Biol Psychiatry. 2019;Jan;20(1):51-63. doi: 10.1080/15622975.2017.1333146
  17. Costa SP, Lage LV, da Mota LM. Fibromyalgia in primary antiphospholipid (Hughes) syndrome. Lupus. 2011;20(11):1182-6. doi: 10.1177/0961203311411962
  18. Лисицына Т.А., Вельтищев Д.Ю., Серавина О.Ф. и др. Сравнительный анализ расстройств тревожно-депрессивного спектра у больных ревматическими заболеваниями. Терапевтический архив. 2018;90(5):30-7 [Lisitsyna TA, Veltishhev DJu, Seravina OF, et al. Comparative analysis of anxiety-depressive spectrum disorders in patients with rheumatic diseases. Therapeutic Аrchive. 2018;90(5):30-7 (In Russ.)]. doi: 10.26442/terarkh201890530-37
  19. Katzav A, Ben-Ziv T, Blank M, et al. Antibody-specific behavioral effects: Intracerebroventricular injection of antiphospholipid antibodies induces hyperactive behavior while anti-ribosomal-P antibodies induces depression and smell deficits in mice. J Neuroimmunol. 2014;272(1-2):10-5. doi: 10.1016/j.jneuroim.2014.04.003
  20. Frauenknecht K, Katzav A, Weiss Lavi R, et al. Mice with experimental antiphospholipid syndrome display hippocampal dysfunction and a reduction of dendritic complexity in hippocampal CA1 neurones. Neuropathol App Neurobiol. 2015;41(5):657-71. doi: 10.1111/nan.12180
  21. Frauenknecht K, Katzav A, Grimm C, et al. Neurological impairment in experimental antiphospholipid syndrome is associated with increased ligand binding to hippocampal and cortical serotonergic 5-HT1A receptors. Immunobiology. 2013;218(4):517-26. doi: 10.1016/ j.imbio.2012.06.011
  22. Frauenknecht K, Katzav A, Grimm C, et al. Altered receptor binding densities in experimental antiphospholipid syndrome despite only moderately enhanced autoantibody levels and absence of behavioral features. Immunobiology. 2014;219(5):341-9. doi: 10.1016/j.imbio.2013.11.006
  23. Postal M, Lapa AT, Sinicato NA, et al. Depressive symptoms are associated with tumor necrosis factor alpha in systemic lupus erythematosus. J Neuroinflam. 2016;13(1):1-7. doi: 10.1186/s12974-015-0471-9
  24. Koshiyama D, Kirihara K, Tada M, et al. Electrophysiological evidence for abnormal glutamate-GABA association following psychosis onset. Translat Psychiatry. 2018;8(1). doi: 10.1038/s41398-018-0261-0
  25. Duman RS, Sanacora G, Krystal JH. Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments. Neuron. 2019;102(1):75-90. doi: 10.1016/ j.neuron.2019.03.013
  26. Lewis DA. Inhibitory neurons in human cortical circuits: Substrate for cognitive dysfunction in schizophrenia. Curr Opin Neurobiol. 2014;26:22-6. doi: 10.1016/j.conb.2013.11.003
  27. Orhan F, Fatouros-Bergman H, Goiny M, et al. CSF GABA is reduced in first-episode psychosis and associates to symptom severity. Mol Psychiatry. 2018;23(5):1244-50. doi: 10.1038/mp.2017.25
  28. Tisseverasinghe A, Peschken C, Hitchon C. Anxiety and Mood Disorders in Systemic Lupus Erythematosus: Current Insights and Future Directions. Curr Rheumatol Reports. 2018;20(12):85. doi: 10.1007/s11926-018-0797-2
  29. Strawbridge R, Arnone D, Danese A, et al. Inflammation and clinical response to treatment in depression: A meta-analysis. Eur Neuropsychopharmacol. 2015. doi: 10.1016/j.euroneuro.2015.06.007
  30. Лисицына Т.А., Вельтищев Д.Ю., Насонов Е.Л. Стрессовые факторы и депрессивные расстройства при ревматических заболеваниях. Научно-практическая ревматология. 2013;51(2):98-103 [Lisitsyna TA, Veltishchev DYu, Nasonov EL. Stressors and depressive disorders in rheumatic diseases. Stressors and depressive disorders in rheumatic diseases. Rheumatology Science and Practice. 2013;51(2):98-103 (In Russ.)]. doi: 10.14412/1995-4484-2013-634
  31. Лисицына Т.А., Вельтищев Д.Ю., Краснов В.Н. и др. Клинико-патогенетические взаимосвязи иммуновоспалительных ревматических заболеваний и психических расстройств. Клиническая медицина. 2014:12-20 [Lisitsina TA, Veltishchev DYu, Krasnov VN, et al. Clinical and pathogenetic relationships between immuno-inflammatory rheumatic diseases and psychic disorders. Klinicheskaja medicina. 2014:12-20 (In Russ.)].
  32. Kao CH, Lan JL, Hsieh JF, et al. Evaluation of regional cerebral blood flow with 99mTc-HMPAO in primary antiphospholipid antibody syndrome. J Nuclear Med. 1999;40(9):1446-50.
  33. Решетняк Т.М., Середавкина Н.В., Насонов Е.Л. и др. Гипергомоцистеинемия – фактор риска тромбоза при антифосфолипидном синдроме? Тромбоз, гемостаз и реология. 2019 [Reshetnyak TM, Seredavkina NV, Nasonov EL, et al. Is hyperhomocysteinemia a risk factor of thrombosis in antiphospholipid syndrome? Tromboz, gemostaz i reologiya. 2019 (In Russ.)]. doi: 10.25555/THR.2019.2.0878
  34. Ezeoke A, Mellor A, Buckley P, Miller B. A systematic, quantitative review of blood autoantibodies in schizophrenia. Schizophr Res. 2013;150(1):245-51. doi: 10.1016/j.schres.2013.07.029
  35. Yelnik CM, Kozora E, Appenzeller S. Non-stroke Central Neurologic Manifestations in Antiphospholipid Syndrome. Curr Rheumatol Reports. 2016;18(2):1-9. doi: 10.1007/s11926-016-0568-x
  36. Sokol DK, O’Brien RS, Wagenknecht DR, et al. Antiphospholipid antibodies in blood and cerebrospinal fluids of patients with psychosis. J Neuroimmunol. 2007. doi: 10.1016/j.jneuroim.2007.08.002
  37. Sirota P, Bogdanov I, Katzav A, et al. Reduced anticardiolipin antibodies in first episode and chronic schizophrenia. Psychiatry Res. 2006;144(2-3):211-6. doi: 10.1016/j.psychres.2006.02.002
  38. Общероссийская общественная организация «Ассоциация ревматологов России». Федеральные клинические рекомендации по диагностике и лечению системной красной волчанки. 2013; с. 1-41 [Assosiation of rheumatologists of Russia. Federal’nye klinicheskie rekomendacii po diagnostike i lecheniyu sistemnoj krasnoj volchanki. 2013; p. 1-41 (In Russ.)].
  39. Masopust J, Malý R, Vališ M. Risk of venous thromboembolism during treatment with antipsychotic agents. Psychiatry Clin Neurosci. 2012;66:541-52. doi: 10.1111/pcn.12001
  40. Delluc A, Rousseau A, Le Galudec M, et al. Prevalence of antiphospholipid antibodies in psychiatric patients users and non-users of antipsychotics. Br J Haematol. 2014;164:272-9. doi: 10.1111/bjh.12627
  41. Федеральные клинические рекомендации по диагностике и лечению психических расстройств эпилепсии. 2013 [Federal clinical guidelines for the diagnosis and treatment of mental disorders of epilepsy. 2013 (In Russ.)].
  42. Sanna G, D’Cruz D, Cuadrado MJ. Cerebral Manifestations in the Antiphospholipid (Hughes) Syndrome. Rheum Dis Clin North Am. 2006;32(3):465-90. doi: 10.1016/j.rdc.2006.05.010
  43. Devinsky O, Schein A, Najjar S. Epilepsy associated with systemic autoimmune disorders. Epilepsy Curr. 2013;3(2):62-8. doi: 10.5698/1535-7597-13.2.62
  44. Liimatainen S, Peltola M, Fallah M, et al. The high prevalence of antiphospholipid antibodies in refractory focal epilepsy is related to recurrent seizures. Eur J Neurol. 2009;16:134-41. doi: 10.1111/j.1468-1331.2008.02373.x
  45. Abreu MM, Danowski A, Wahl DG, et al. The relevance of “non-criteria” clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev. 2015;14(5):401-14. doi: 10.1016/j.autrev.2015.01.002
  46. Krause I, Lev S, Fraser A, et al. Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome. Ann Rheum Dis. 2005;64. Issue 10. doi: 10.1136/ard.2004.032813
  47. Cimaz R, Meroni PL, Shoenfeld Y. Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome). Lupus. 2006;15(4):191-7. doi: 10.1191/0961203306lu2272rr
  48. Peltola JT, Haapala AM, Isojärvi JI, et al. Antiphospholipid and antinuclear antibodies in patients with epilepsy or new-onset seizure disorders. Am J Med. 2000. doi: 10.1016/S0002-9343(00)00617-3
  49. Hawro T, Bogucki A, Krupińska-Kun M, et al. Intractable headaches, ischemic stroke, and seizures are linked to the presence of anti-β2GPI antibodies in patients with systemic lupus erythematosus. PLoS ONE. 2015. doi: 10.1371/journal.pone.0119911
  50. Ranua J, Luoma K, Peltola J, et al. Anticardiolipin and antinuclear antibodies in epilepsy - A population-based cross-sectional study. Epilepsy Res. 2004. doi: 10.1016/j.eplepsyres.2003.12.004
  51. Peluso S, Antenora A, De Rosa A, et al. Antiphospholipid-related chorea. Front Neurol. 2012. doi: 10.3389/fneur.2012.00150
  52. Nagano J, Sudo N, Nagaoka S, et al. Life events, emotional responsiveness, and the functional prognosis of patients with rheumatoid arthritis. BioPsychoSoc Med. 2015. doi: 10.1186/s13030-015-0043-3
  53. Ищенко Д.А., Вельтищев Д.Ю., Ковалевская О.Б. и др. Психотравмирующие факторы и расстройства тревожно-депрессивного спектра при болезни Бехчета (междисциплинарное исследование). Журнал неврологии и психиатрии им. С.С. Корсакова. 2014 [Ishchen- ko DA, Veltishchev DYu, Kovalevskaya O.B, et al. Psychotraumatic factors and disorders of the anxiety-depressive spectrum in Behcet’s disease (interdisciplinary study). S.S. Korsakov Journal of Neurology and Psychiatry. 2014 (In Russ.)].
  54. Manolache L, Petrescu-Seceleanu D, Benea V. Life events involvement in psoriasis onset/recurrence. Int J Dermatol. 2010. doi: 10.1111/j.1365-4632.2009.04367.x
  55. Stojanovich L, Marisavljevich D. Stress as a trigger of autoimmune disease. Autoimmun Rev. 2008;7(3):209-13. doi: 10.1016/j.autrev.2007.11.007
  56. Dube SR, Fairweather D, Pearson WS, et al. Cumulative childhood stress and autoimmune diseases in adults. Psychosomatic Med. 2009. doi: 10.1097/PSY.0b013e3181907888
  57. Wegman HL, Stetler C. A meta-analytic review of the effects of childhood abuse on medical outcomes in adulthood. Psychosomatic Med. 2009. doi: 10.1097/PSY.0b013e3181bb2b46
  58. Stojanovich L. The catastrophic antiphospholipid syndrome in Serbia: Diagnostic and management problems. Clin Rev Allergy Immunol. 2009;36(2-3):98-103. doi: 10.1007/s12016-008-8102-1
  59. Лызлов А.В., Серавина О.Ф., Ковалевская О.Б. Аффективность как структурообразующая основа антропологических пространств: философия, психология, психиатрия. Вопросы психологии. 2010 [Lyz- lov AV, Seravina OF, Kovalevskaja OB. Affectivity as a structure-forming basis of anthropological spaces: philosophy, psychology, psychiatry. Voprosy psihologii. 2010 (In Russ.)].
  60. Yelnik CM, Kozora E, Appenzeller S. Cognitive disorders and antiphospholipid antibodies. Autoimmun Rev. 2016;15(12):1193-8. doi: 10.1016/j.autrev.2016.09.002
  61. Cervera R, Piette JC, Font J, et al; Euro-Phospholipid Project Group. Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthrit Rheumat. 2002. doi: 10.1002/art.10187
  62. Калашникова Л.А. Цереброваскулярные нарушения при антифосфолипидном синдроме. Анналы клинической и экспериментальной неврологии. 2011:39-43 [Kalashnikova LA. Cerebrovascular disorders in antiphospholipid syndrome. Annals of clinical and experimental neurology. 2011:39-43 (In Russ.)].
  63. Chapman J, Abu-Katash M, Inzelberg R, et al. Prevalence and clinical features of dementia associated with the antiphospholipid syndrome and circulating anticoagulants. J Neurol Sci. 2002. doi: 10.1016/S0022-510X(02)00271-X
  64. Kozora E, Hanly JG, Lapteva L, Filley CM. Cognitive dysfunction in systemic lupus erythematosus: Past, present, and future. Arthrit Rheumat. 2008. doi: 10.1002/art.23991
  65. Alarcón GS, Cianfrini L, Bradley LA, et al; Lumina Study Group. Systemic lupus erythematosus in three ethnic groups. X. Measuring cognitive impairment with the cognitive symptoms inventory. Arthrit Care Res. 2002. doi: 10.1002/art.10457
  66. Vargas JV, Vaz CJ. Evaluation of central nervous system involvement in SLE patients. Screening psychiatric manifestations – a systematic review. Acta Reumatol Port. 2014;39:208-17.
  67. Denburg SD, Carbotte RM, Ginsberg JS, Denburg JA. The relationship of antiphospholipid antibodies to cognitive function in patients with systemic lupus erythematosus. J Int Neuropsychol Soc. 1997.
  68. Kozora E, Erkan D, Zhang L, et al. Cognitive dysfunction in antiphospholipid antibody (aPL)-negative systemic lupus erythematosus (SLE) versus aPL-positive non-SLE patients. Clin Exper Rheumatol. 2014;32(1):34-40.
  69. Weiss R, Bitton A, Ben Shimon M, et al. Annexin A2, autoimmunity, anxiety and depression. J Autoimmun. 2016;73:92-9. doi: 10.1016/j.jaut.2016.06.011
  70. Nalli C, Iodice A, Andreoli L, et al. Long-term neurodevelopmental outcome of children born to prospectively followed pregnancies of women with systemic lupus erythematosus and/or antiphospholipid syndrome. Lupus. 2017;26(5):552-8. doi: 10.1177/0961203317694960
  71. Katzav A, Faust-Socher A, Kvapil F, et al. Antiphospholipid syndrome induction exacerbates a transgenic Alzheimer disease model on a female background. Neurobiol Aging. 2011. doi: 10.1016/j.neurobiolaging.2009.02.007
  72. Herz J. Apolipoprotein E receptors in the nervous system. Curr Opin Lipidol. 2009. doi: 10.1097/MOL.0b013e32832d3a10
  73. Atzeni F, Pipitone N, Iaccarino L, et al. Rheumatic diseases and autoimmune vascular dementia. Autoimmun Rev. 2017. doi: 10.1016/j.autrev.2017.10.011
  74. Donzis EJ, Tronson NC. Modulation of learning and memory by cytokines: Signaling mechanisms and long term consequences. Neurobiol Learning Memory. 2014. doi: 10.1016/j.nlm.2014.08.008
  75. Brites D, Fernandes A. Neuroinflammation and Depression: Microglia Activation, Extracellular Microvesicles and microRNA Dysregulation. Front Cell Neurosci. 2015. doi: 10.3389/fncel.2015.00476
  76. Mackay M. Lupus brain fog: a biologic perspective on cognitive impairment, depression, and fatigue in systemic lupus erythematosus. Immunol Res. 2015;63(1-3):26-37. doi: 10.1007/s12026-015-8716-3
  77. Cavaco S, Martins Da Silva A, Santos E, et al. Are cognitive and olfactory dysfunctions in neuropsychiatric lupus erythematosus dependent on anxiety or depression? J Rheumatol. 2012;39(4):770-6. doi: 10.3899/jrheum.110574
  78. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment meta-analysis of the effects of anxiety and depression on patient adherence. Arch Int Med. 2000. doi: 10.1001/archinte.160.14.2101
  79. Лисицына Т.А., Зелтынь А.Е., Вельтищев Д.Ю. и др. Когнитивные нарушения и расстройства тревожно-депрессивного спектра у больных ревматоидным артритом. Журнал неврологии и психиатрии. 2012 [Lisitsyna TA, Zeltyn AE, Veltishchev D.Yu, et al. Cognitive impairment and anxiety-depressive disorders in patients with rheumatoid arthritis. Zhurnal nevrologii i psihiatrii. 2012 (In Russ.)].
  80. Овчаров П.С., Лисицына Т.А., Вельтищев Д.Ю. и др. Когнитивные нарушения при болезни Бехчета. Журнал неврологии и психиатрии. 2019:10-6 [Ovcharov PS, Lisitsyna TA, Veltishchev DYu, et al. Cognitive disorders in Behçet’s disease. Zhurnal nevrologii i psihiatrii. 2019:10-6 (In Russ.)]. doi: 10.17116/jnevro201911902110
  81. Nantes SG, Su J, Dhaliwal A, et al. Performance of screening tests for cognitive impairment in systemic lupus erythematosus. J Rheumatol. 2017;44(11):1583-9. doi: 10.3899/jrheum.161125
  82. Georgopoulou S, Efraimidou S, Maclennan SJ, et al. Antiphospholipid (Hughes) syndrome: description of population and health-related quality of life (HRQoL) using the SF-36. Lupus. 2015; p. 174-9. doi: 10.1177/0961203314551809
  83. Georgopoulou S, Efraimidou S, MacLennan SJ et al. The relationship between social support and health-related quality of life in patients with antiphospholipid (hughes) syndrome. Modern Rheumatol. 2018;28(1):147-55. doi: 10.1080/14397595.2017.1317319
  84. Воробьева Л.Д., Асеева Е.А. Значение качества жизни, связанного со здоровьем, у больных системной красной волчанкой и современные инструменты его оценки. Cовременная ревматология. 2017;11(4):62-72 [Vorobyeva LD, Aseeva EA. Importance of health-related quality of life and its current assessment tools in patients with systemic lupus erythematosus. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2017;11(4):62-72 (In Russ.)]. doi: 10/14412/1996-7012-2017-4-62-72.
  85. Вельтищев Д.Ю., Марченко А.С., Серавина О.Ф., Ковалевская ОБ. Аффективно-стрессовая модель депрессии: практическое внедрение в ревматологической практике. Психиатрия и психофармакотерапия. 2009. [Vel’tishhev DJu, Marchenko AS, Seravina OF, Kovalevskaya OB. Affective-stress model of depression: practical implementation in rheumatological practice. Psychiatry and Psychopharmacotherapy. 2009 (In Russ.)].
  86. Alsowaida N, Alrasheed M, Mayet A, et al. Medication adherence, depression and disease activity among patients with systemic lupus erythematosus. Lupus. 2017:1-6. doi: 10.1177/0961203317725585
  87. Российские клинические рекомендации. Ревматология. Под ред. Е.Л. Насонова. М.: ГЭОТАР-Медиа, 2017: Лисицына Т.А., Вельтищев Д.Ю., Серавина О.Ф. и др. Рекомендации по диагностике и лечению психических расстройств при ревматических заболеваниях; с. 411-34 [Russian clinical recommendations. Rheumatology. edited by Nasonov EL. Moscow: GEOTAR-Media. 2017: Lisicyna TA, Vel’tishchev DYu, Seravina OF, et al. Recommendations for the diagnosis and treatment of mental disorders in rheumatic diseases; p. 411-34 (In Russ.)].
  88. Yuet WC, Derasari D, Sivoravong J, et al. Selective Serotonin Reuptake Inhibitor Use and Risk of Gastrointestinal and Intracranial Bleeding. J Am Osteopathic Assoc. 2019;119(2):102. doi: 10.7556/jaoa.2019.016
  89. Frew JW. The clinical significance of drug interactions between dermatological and psychoactive medications. Dermatol Therapy. 2014;27(1):1-11. doi: 10.1111/dth.12003

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies